Fig. 1From: A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanomaWaterfall plot depicting best response as a percentage change from baseline of target lesions. irRC cutoffs for partial response and progressive disease are shown (dotted lines)Back to article page